Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis

Biologics are potent immunomodulatory drugs, whose application in the treatment of psoriasis has shown extremely good therapeutic results and a satisfactory safety profile. The administration of these agents in special cases, such as in patients with HIV infection, previous malignancy, unclear vacci...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of dermatology Vol. 58; no. 9; pp. 1008 - 1013
Main Authors Plachouri, Kerasia‐Maria, Georgiou, Sophia
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.09.2019
Subjects
Adult
Age Factors
Biological Products - therapeutic use
Child
Dermatologic Agents - therapeutic use
Dermatology - standards
Extreme values
HIV
HIV Infections - complications
HIV Infections - immunology
Human immunodeficiency virus
Humans
Immunization
Immunomodulation
Immunosuppressive Agents - therapeutic use
Infections
Malignancy
Medical History Taking
Neoplasms - complications
Neoplasms - immunology
Patients
Practice Guidelines as Topic
Psoriasis
Psoriasis - drug therapy
Psoriasis - immunology
Treatment Outcome
Upgrading
Vaccination
Vaccination - methods
Viruses
Online AccessGet full text

Cover

More Information
Summary:Biologics are potent immunomodulatory drugs, whose application in the treatment of psoriasis has shown extremely good therapeutic results and a satisfactory safety profile. The administration of these agents in special cases, such as in patients with HIV infection, previous malignancy, unclear vaccination status as well as children, can be challenging. This report is an updated systematic review of the use of biologics in the above‐mentioned groups. Articles derived from the databases PubMed, EMBASE, and SCOPUS, and published between 1989 and 2018, were analyzed for this study. The existing evidence is not in all cases sufficient in order to provide adequate insight on the management of these complex situations. The aim of this report is to present a summarized update on the knowledge of this special topic so far and to draw into attention the need to conduct more systematic studies so as to clarify the best therapeutic strategies for these special patient groups when it comes to the use of biologics.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:0011-9059
1365-4632
DOI:10.1111/ijd.14436